TY - JOUR T1 - Associations between gestational weight gain adequacy and neonatal outcomes in Tanzania JF - medRxiv DO - 10.1101/2021.08.19.21262273 SP - 2021.08.19.21262273 AU - Nandita Perumal AU - Dongqing Wang AU - Anne Marie Darling AU - Molin Wang AU - Enju Liu AU - Willy Urassa AU - Andrea Pembe AU - Wafaie W. Fawzi Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/25/2021.08.19.21262273.abstract N2 - Introduction Gestational weight gain (GWG) is associated with fetal and newborn health; however, data from sub-Saharan Africa are limited.Methods We used data from a prenatal micronutrient supplementation trial among a cohort of HIV-negative pregnant women in Dar es Salaam, Tanzania to estimate the relationships between GWG and newborn outcomes. GWG adequacy was defined as the ratio of the total observed weight gain over the recommended weight gain based on the Institute of Medicine body mass index (BMI)-specific guidelines. Newborn outcomes assessed were: stillbirth, perinatal death, preterm birth, low birthweight, macrosomia, small-for-gestational age (SGA), large-for-gestational age (LGA), stunting at birth, and microcephaly. Modified Poisson regressions with robust standard error were used to estimate the relative risk of newborn outcomes as a function of GWG adequacy.Results Of 7561 women included in this study, 51% had severely inadequate (<70%) or inadequate GWG (70-90%), 31% had adequate GWG (90-125%), and 18% had excessive GWG (≥125%). Compared to adequate GWG, severely inadequate GWG was associated with a higher risk of low birthweight, SGA, stunting at birth, and microcephaly; whereas excessive GWG was associated with a higher risk of LGA and macrosomia.Conclusion Interventions to support optimal gestational weight gain are needed and are likely to improve newborn outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported in part by funding from the Bill and Melinda Gates Foundation (OP1204850) and the Canadian Institutes of Health Research Fellowship to NP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Trial protocol was approved by the Institutional Reviews Boards at the Harvard T.H Chan School of Public Health and Muhimbili University of Health and Allied Sciences (MUHAS) in Tanzania. Only de-identified secondary data was used in this study and therefore exempt from full review by the Institutional Review Board of the Harvard T.H. Chan School of Public Health.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are not publicly available due to ethical reasons. ER -